Viking Therapeutics Files 8-K on Shareholder Votes & Exhibits
Ticker: VKTX · Form: 8-K · Filed: May 27, 2025 · CIK: 1607678
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, financial-reporting
Related Tickers: VKTX
TL;DR
Viking Therapeutics (VKTX) filed an 8-K on May 27th covering shareholder votes and financial exhibits from May 20th.
AI Summary
Viking Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits as of May 20, 2025. The filing details the company's principal executive offices in San Diego, California, and its standard industrial classification in Pharmaceutical Preparations.
Why It Matters
This filing provides an update on corporate governance and financial reporting for Viking Therapeutics, which is crucial for investors to understand the company's operational and regulatory status.
Risk Assessment
Risk Level: low — This is a routine regulatory filing detailing corporate actions and financial reporting, not indicating new material risks.
Key Numbers
- 001-37355 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-1073877 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- May 20, 2025 (date) — Earliest event reported
- May 27, 2025 (date) — Filing date
- San Diego, California (location) — Principal Executive Offices
- 9920 Pacific Heights Blvd, Suite 350 (address) — Business Address
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What financial statements and exhibits are included in this filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific content of these statements and exhibits is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated May 20, 2025.
What is Viking Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 9920 Pacific Heights Blvd, Suite 350, San Diego, California, 92121.
What is Viking Therapeutics, Inc.'s Standard Industrial Classification code?
The company's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 27, 2025 regarding Viking Therapeutics, Inc. (VKTX).